At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 195 enrolled
Drug / intervention
TAC-302 +1 moredrug
Likely dose
TAC-302 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
In Brief
A Phase 2 clinical trial evaluating TAC-302 and Placebo for Detrusor Underactivity and Overactive Bladder. Completed, enrolled 195 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDetrusor Underactivity, Overactive Bladder
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartSep 2017
Primary CompletionNov 2019
Study CompletionMar 2020
TodayJul 2026
First PostedJun 5, 2017
Enrollment StartSep 9, 2017
Primary CompletionNov 1, 2019
Study CompletionMar 27, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.1 years ago
Interventions
TAC-302drug
TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
Placebodrug
Placebo administered orally twice per day after meals, for 12 weeks.